Abstract: Dual infection of 12 day-old quail (Colinus uirginianus) with 10 6 plaque forming units of CELO virus and low doses of avian adeno-associated virus (A-AV), resulted in significant enhancement of CELO virus-induced mortality, whereas dual infections with high doses of A-AV resulted in a delay in mortality. A-AV induced enhancement and inhibition of CELO virus pathogenicity could be blocked by the addition of A-AV antiserum prior to infection.
INTRODUCTION
Quail bronchitis virus (QBV), an avian adenovirus was isolated originally from juvenile bobwhite quail (Colinus  uirginianus) with acute respiratory disease. 4 In field outbreaks the disease is typified by its rapid spread, and high mortality.
2 ! 4 Quail chicks experimentally infected with serially passaged QBV fail to contract the disease in its acute form. 2 Chicken embryo lethal orphan (CELO) virus was isolated as a contaminant from chicken embryos. 10 It was designated CELO because of its pathogenicity for the chicken embryo. Initially, no disease could be ascribed to it. The virus was thought to cause only inapparent infections in chickens and other avian species. 15 Both isolates have since been shown to be type 1 avian adenoviruses (AV). 2 They differ only in that QBV stocks have been shown to contain a defective parvovirus, avian adenovirus-associated virus (A-AV), 9 which requires a host cell coinfected with a "helper" AV for productive infection. 8 A-AV has been shown to enhance or inhibit CELO virus plaque production in cell culture depending upon the dosage used. 6 In view of these observations, it was felt that A-AV might have an effect on the pathogenesis of CELO virus in quail.
In this study, the effect of varying A-AV dosage on the pathogenicity of CELO virus in quail was investigated.
MATERIALS AND METHODS
Three-times plaque-purified type 1 avian AV (CELO strain) was propagated in chicken embryo kidney (CEK) cells prepared from CELO-free embryonated eggs.
51 Stock preparations were maintained free of avian A-AV contamination. Avian A-AV was purified by equilibrium cesium chloride centrifugation from the Olson strain of QBV which was propagated in chicken embryos as previously described. 8 CELO virus infectivity was assayed by plaque production in CEK cells. 1 While avian A-AV infectivity was assayed by determining the 50% infectious dose (ID 50 ) endpoint 7 using the method of Pronovost. Bobwhite quail were purchased from a commercial source m and raised under conditions of semi-isolation. Birds were housed in wire-floored heated brooders and maintained on a commercial preparation of chick starter feed and water ad libitum. Thirteen groups of 15 birds all identical in weight were formed. The quail were then infected or otherwise treated at 12 days of age. The inoculums consisted of 10 fi plaque forming units (PFU) of CELO virus alone or in combination with varying dosage of A-AV (10 2 , 10\ 10«, 10" ID 5II ). All viruses were given intraperitoneally (IP) behind the left leg. Birds were examined daily for clinical signs and mortality. Fecal samples were collected at 9 days postinfection (PI) for virus reisolation. Sera from acute and convalescent cases were collected for detection of AAV and AV antibody. All surviving birds were killed at 14 days PI.
Controls employed in addition to CELO virus alone were: (1) uninfected quail; (2) quail inoculated with diluent alone; (3) two groups of quail infected with A-AV, one receiving a high and the other a low dose in addition to CELO virus, after absorption with A-AV antiserum; (4) two groups of quail infected with A-AV alone, a high and a low dose; (5) two groups of quail, one infected with a high and the other a low A-AV dose after absorption with A-AV antiserum. High (10« ID ftll ) and low (10* ID,,,) doses of A-AV were used in the instance of all A-AV or A-AV blocking controls because the activity of A-AV was not known. In all blocking controls A-AV activity was blocked with homologous rabbit A-AV antiserum. Differences in mortality between treatment and control groups were made using-the Chi-square test.
RESULTS
Overall mortality was 13.3% (maximum at 4 days PI) in the control group receiving 10 H PFU CELO virus alone (Table 1) . Dual infection with 10 ,; PFU CELO virus and 10 2 or 10' ID r ", A-AV resulted in significant enhancement (p < 0.05) of CELO virus-induced mortality. Maximum enhancement was observed with 10 4 ID 5D AAV. Dual infection with 10 6 PFU CELO virus and 10 e or 10* ID 5 " A-AV resulted in a delay in CELO virusinduced mortality (maximum at 6-7 days PI) ( Table 1) .
Uninfected quail or quail receiving only the diluent did not show signs of morbidity or mortality. Homologous rabbit antiserum to A-AV blocked the enhancing and inhibitory effects of A-AV and gave mortality rates similar to the positive control group receiving CELO virus alone. Inoculation of quail with A-AV alone also gave mortality rates similar to the positive control group receiving CELO virus alone. This effect was blocked, however, with homologous A-AV antiserum ( Table 2) .
Postmortem examination of infected quail revealed petechial and ecchymotic hemorrhages of the liver and heart. The lesions were similar whether the infection had been initiated with CELO alone or in combination with A-AV.
In this trial, serum samples from all dually infected groups were positive for CELO virus and A-AV antibody, as determined by the immunodiffusion (ID) test at 14 days PI. CELO virus was reisolated from all groups except those quail that received only the A-AV, in which no reisolation attempt was made. No reisolation attempt was made for those groups receiving A-AV alone, since the presence of the adenovirus is required for a productive A-AV infection. Reisolation of the adenovirus, in dually infected birds, in conjunction with a sero-positive ID test for A-AV confirmed the presence of these viruses.
DISCUSSION
Avian A-AV has been viewed as a common contaminant of AV stocks with Avian A-AV induced enhancement and inhibition of CELO and Tipton virus plaque production has been reported." Low levels of A-AV (1-40 ID 5( /cell) significantly enhanced whereas high levels of A-AV (> 40 ID 50 /cell) significantly inhibited plaque production. AV serotypes showed variations in responses which were found to correlate well with serotype growth rates.
B
Further studies are required to resolve the question as to whether a high dosage of A-AV (108 IDso ) wi n inhibit CELO induced quail mortality. In this study, the difference between the control and treated groups was one bird out of 15 (Table 1) . This difference was too small to be significant. However, the 2-3 day delay in death, of A-AV treated birds suggests that some inhibitory effect was present. Although no significant evidence supporting an inhibitory effect was found in this study, Pronovost' reported such an effect using high dosages of A-AV. Inoculation trials using greater numbers of birds may illustrate more dramatically inhibition by A-AV of CELO induced quail mortality.
The mortality observed following inoculation of the quail with A-AV alone could be due to reactivation of endogenous AV, which may be present in quail purchased from a commercial source. Further support for such a reactivation hypothesis, as opposed to contamination by residual AV, is that the purified A-AV preparations were absorbed with CELO virus antiserum prior to use. The absence of plaque formation, in cell cultures inoculated with these preparations, was a further indication of purity.
Data suggesting in vivo enhancement by A-AV was interpreted as anomalous in an earlier study by Mayor et a/.
:l The latter author inoculated pregnant hamsters with A-AV in an attempt to suppress AV-induced tumor production in offspring and contrary to expected results, the number of induced tumors in female off-spring was considerably increased. This phenomenon was examined no further. The observation, however, supports our findings that avian A-AV, under certain conditions, can enhance the pathogenicity of an avian AV infection in vivo.
